Travere Therapeutics (TVTX) Projected to Post Earnings on Thursday

Travere Therapeutics (NASDAQ:TVTX - Get Free Report) will likely be issuing its quarterly earnings data before the market opens on Thursday, February 20th. Analysts expect the company to announce earnings of ($0.62) per share and revenue of $72.38 million for the quarter. Parties that wish to register for the company's conference call can do so using this link.

Travere Therapeutics Stock Performance

TVTX traded down $0.81 on Friday, reaching $22.91. 1,466,790 shares of the stock were exchanged, compared to its average volume of 1,303,585. The company's 50-day moving average price is $19.22 and its 200 day moving average price is $16.19. Travere Therapeutics has a fifty-two week low of $5.12 and a fifty-two week high of $25.29. The company has a debt-to-equity ratio of 24.96, a current ratio of 1.71 and a quick ratio of 1.68. The firm has a market capitalization of $1.79 billion, a PE ratio of -5.04 and a beta of 0.72.

Insiders Place Their Bets

In other news, insider Peter Heerma sold 1,584 shares of the company's stock in a transaction that occurred on Wednesday, January 22nd. The stock was sold at an average price of $18.94, for a total value of $30,000.96. Following the completion of the sale, the insider now directly owns 106,374 shares in the company, valued at $2,014,723.56. This represents a 1.47 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CAO Sandra Calvin sold 54,244 shares of the stock in a transaction that occurred on Tuesday, February 11th. The shares were sold at an average price of $25.00, for a total value of $1,356,100.00. Following the completion of the sale, the chief accounting officer now directly owns 54,410 shares of the company's stock, valued at approximately $1,360,250. This represents a 49.92 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 218,425 shares of company stock worth $4,674,259. Corporate insiders own 3.75% of the company's stock.

Wall Street Analyst Weigh In

TVTX has been the subject of a number of research reports. Canaccord Genuity Group lifted their price target on Travere Therapeutics from $22.00 to $45.00 and gave the stock a "buy" rating in a research report on Wednesday. Cantor Fitzgerald began coverage on Travere Therapeutics in a report on Friday, January 10th. They issued an "overweight" rating for the company. Barclays boosted their price objective on Travere Therapeutics from $18.00 to $20.00 and gave the company an "overweight" rating in a report on Friday, November 1st. Scotiabank lifted their price target on Travere Therapeutics from $27.00 to $32.00 and gave the company a "sector outperform" rating in a research note on Wednesday. Finally, Wells Fargo & Company upgraded Travere Therapeutics from an "equal weight" rating to an "overweight" rating and lifted their price target for the company from $9.00 to $27.00 in a research note on Monday, October 21st. One equities research analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $27.77.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.